JP2010254578A - Wheat fermentation extract composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a wheat fermentation extract composition which can induce an effect for improving blood glucose levels in preliminary abnormal lipid diseases and an effect for improving abnormal lipid diseases in preliminary diabetes reserves. <P>SOLUTION: The wheat fermentation extract composition includes a wheat fermentation extract and a Salacia plant extract. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to a wheat fermented extract blend having a preventive effect on lifestyle-related diseases and the like.

  In recent years, in many countries, including Japan, the establishment of a stable food supply system and the stabilization of prices have made it possible to consume calories very inexpensively. Along with this, lifestyle-related diseases (diabetes, dyslipidemia (hyperlipidemia), hypertension, etc.) due to excessive caloric intake are widespread worldwide and many patients arise. Because of the enormous cost of this treatment, the increase in financial burden due to the increase in individual household and government social security costs has become a major social problem. Therefore, in order to improve obesity due to excessive caloric intake, which is the main cause of lifestyle-related diseases, it is considered important to reduce metabolic syndrome. Currently, 50% of men aged 40 to 70 and 20% of women are considered to be affected by the metabolic syndrome or are in the reserve group. There is a need for efforts to reduce it.

  Among lifestyle-related diseases, there are many patients with dyslipidemia (decrease in HDL (high density lipoprotein), increase in LDL (low density lipoprotein)), and there are about 31 million people in Japan (Non-patent Document 1). ). Dyslipidemia causes arteriosclerosis (decreased elasticity of blood vessels, narrowing of blood vessel lumens), and causes onset of hypertension, myocardial infarction, and the like. The main causes of dyslipidemia are a decrease in HDL, which is lipid in blood, and an increase in LDL (lipid abnormality) due to genetic factors, high calories, high fat diet, excessive intake of salt, lack of exercise, and the like. Treatment is performed by pharmacotherapy that lowers LDL in the blood by modifying dietary habits, inhibiting cholesterol synthesis, and promoting bile acid / cholesterol excretion.

  Diabetes known as a lifestyle-related disease is said to currently have 4 million patients (Non-patent Document 1). It is said that the disease is caused by “insufficient action of insulin (decreased secretion / expression of insulin resistance)” produced by β cells on the islets of Langerhans due to genetic factors, high calorie, high fat diet, lack of exercise, etc. If blood glucose control is insufficient even after dietary therapy and exercise therapy, methods of maintaining good blood glucose control with insulin injections are also actively carried out.

  In order to reduce obesity, it is necessary to increase calorie consumption or reduce calorie intake. Calorie consumption is time consuming and physically burdensome, so it is difficult to sustain. On the other hand, the reduction in calorie intake is difficult to sustain because of the great mental and physical stress that opposes hunger caused by dietary restrictions. Therefore, if a food having an effect of inhibiting the absorption of sugar is ingested, it is difficult to absorb the sugar from the intestinal tract, so that a reduction in calorie intake can be expected. Salacia oblonga (Poncolanchi), which is known as an example thereof, has an α-glycosidase inhibitory action. This mechanism of action is described in the literature (Patent Document 1). In short, the active ingredient of Salacia oblonga competitively and antagonistically inhibits disaccharide-degrading enzymes such as maltase and sucrase located in the mucous membrane of the small intestine, resulting in the breakdown of ingested carbohydrates into glucose and fructose. Will gradually occur. As a result, absorption in the duodenum and upper part of the jejunum decreases, and digestion and absorption occur in the middle and lower part of the small intestine, and the absorption of monosaccharides is performed slowly using the entire small intestine. The effect of slowly delaying the increase in blood glucose level after meals will sustain a feeling of fullness after meals, and will not cause hunger for a long time, thus preventing obesity, suppressing hyperglycemia after meals, and preventing insulin secretion. It is thought that the excessive insulin response is suppressed and the glycemic control state is improved.

  By the way, it is known that diabetes abnormalities are likely to occur in diabetes patients due to insulin abnormality, and dyslipidemia and diabetes may be combined. Since the pathology of diabetes and dyslipidemia are completely different, therapeutic agents for diabetes and dyslipidemia are used, but treatment is generally considered difficult due to concerns about their interaction. Therefore, it is an extremely important issue to prevent both reserve groups from becoming both diseases.

  We have clarified that the water extract of wheat flour contains effective components that activate innate immunity (Patent Document 2, Non-Patent Document 2). It has been found that this component not only activates innate immunity but also has a therapeutic effect on diabetes and hyperlipidemia in humans and mice (Non-patent Document 3). This component is lipopolysaccharide, a membrane component of Pantoea agglomerans, a gram-negative bacterium that coexists with wheat. Furthermore, the wheat fermented extract containing this component was developed. However, there was no result about the improvement effect of the blood sugar level in the dyslipidemia preliminary group of the fermented wheat extract and the improvement effect of dyslipidemia in the diabetes preparatory group.

JP 2000-152744 A International Publication No. 2005/0300938 Japanese Patent Laid-Open No. 9-2963 JP 2001-181194 A Japanese Patent Laid-Open No. 2001-163795

2007 Prescription Drug Data Book No.4 Nishizawa, T. et al, Homeostasis as regulated by activated macrophage.I. Lipopolysaccharide (LPS) from wheat flour: isolation, purification and some biological activities, Chem. Pharm. Bull., 40, 479-483 (1992). Kawauchi Chie et al., Innate immunity of fermented wheat extract, New Food Industry, 48, 19-27 (2006)

  Therefore, we investigated the effect of improving the blood glucose level and dyslipidemia in the lifestyle-related disease preparatory group with the fermented wheat extract, and manufactured the wheat fermented extract beverage added with Salacia oblonga. In addition to the effect of improving blood glucose level in the preparatory group, the effect of improving dyslipidemia in the preparatory group of diabetes was obtained.

  The wheat fermented extract composition of the present invention is an extract obtained by fermenting wheat flour with facultative anaerobic gram-negative bacteria that coexist with plants, and simultaneously culturing the facultative anaerobic gram-negative bacteria (hereinafter, "Wheat fermentation extract") and an extract of a plant of the genus Salacia.

  The wheat fermented extract blend of the present invention is characterized by containing a wheat fermented extract and Salacia oblonga.

  Moreover, the wheat fermented extract blend of the present invention is characterized by containing a fermented wheat extract and an extract of mao, allspice, clove, rafma, keihi, eucalyptus, or loquat.

  Moreover, it is desirable that the wheat fermented extract blend is a pharmaceutical, a pet pharmaceutical, a quasi-drug, a food, a functional food, a pet feed or a bath preparation.

  ADVANTAGE OF THE INVENTION According to this invention, in addition to the improvement effect of the blood glucose level in a dyslipidemia preliminary group, the improvement effect of the dyslipidemia in a diabetes preparatory group can be induced | guided | derived. Furthermore, the pharmaceutical which mix | blended this, the pharmaceutical for pets, a quasi-drug, food, a functional food, the feed for pets, a bath agent, etc. can be provided.

  Hereinafter, embodiments for carrying out the present invention will be described in detail.

I: Fermented wheat extract and lactic acid bacteria sterilized bacterial mixture In this case, we found that a mixed product of fermented wheat extract and Salacia oblonga can express effects that cannot be obtained alone, making it a safe and lifestyle-related disease preparatory group. Effective quasi-drugs, foods, functional foods, and pet feed can be provided.

II: Summary of important points of the invention A combination of fermented wheat extract as an immunostimulatory substance and Salacia oblonga that lowers blood glucose level is novel.

Test method Subjects with fasting blood glucose of 100 to 125 mg / dl (Group A: Preliminary diabetes group), fasting blood glucose of less than 100 mg / dl, neutral fat of 150 mg / dl or more, HDL cholesterol of less than 40 mg / dl, LDL cholesterol Divided into test subject group (Group B: Pre-dyslipidemia group) corresponding to any of 120mg / dl or more, Wheat fermentation extract, Salacia oblonga mixed group (S), Salacia oblonga group (P), Wheat fermentation Divided into extract group (Y). Each group was tested for 60 days. Each group of subjects took one pack at a time, twice a day, and had the tasting timing and physical condition recorded daily on a self-check sheet. Blood tests, general physical surveys, and questionnaire surveys were conducted at partner hospitals before, during, and after the test (around day 30). For statistical analysis, a paired t-test was performed and p <0.05 was considered significant.

Subjects were divided into the following groups and groups.
Group A: (Group S) 5 men, 2 women, 7 in total. (P group) 4 men, 2 women, a total of 6 people. (Group Y) 4 men, 2 women, a total of 6 people.
Group B: (Group S) 8 males and 6 females, 14 in total. (P group) Seven men, seven women, a total of 14 people. (Group Y) 7 men, 6 women, a total of 13 people.

(Age composition)
Group A:
(Group S) Male 49.2 ± 6.3 years old, female 51.0 ± 5.7 years old, total 49.7 ± 5.7 years old.
(Group P) Male 49.5 ± 7.5 years old, female 47.0 ± 5.7 years old, total 48.7 ± 6.5 years old.
(Group Y) Male 47.3 ± 9.5 years old, female 48.5 ± 12.0 years old, total 47.7 ± 9.2 years old.
Group B:
(Group S) Male 48.4 ± 7.6 years old, female 51.5 ± 6.7 years old, total 49.7 ± 7.2 years old.
(P group) Male 45.6 ± 5.4 years old, Female 50.6 ± 10.1 years old, total 48.1 ± 8.2 years old.
(Group Y) Male 48.1 ± 65.9 years old, female 46.2 ± 5.9 years old, total 47.2 ± 6.0 years old.

Method for producing fermented wheat extract
(1) Pantoea agglomerans should be isolated from wheat flour according to standard methods. In addition, once isolated and identified, this bacterium can be stored in 50% glycerol or the like.
(2) 0.05-5% sodium chloride, 0.005-1 mol phosphate buffer, or mixed salt solution (0.5-10% disodium phosphate, 0.05-5% Prepare potassium potassium phosphate, 0.05 to 5% sodium chloride, 0.05 to 5% ammonium chloride) and the like.
(3) Suspend the flour in water to a concentration of 0.05-10%.
(4) Prepare a 0.2 to 3 molar magnesium chloride solution.
(5) A 0.2 to 3 molar calcium chloride solution is prepared.
(6) Sterilize 2 to 5 with an autoclave if necessary.
(7) A suitable amount of 2 to 5 is mixed and water is added to form a suspension containing 0.1 to 5% flour. In some cases, an alkaline solution or an acidic solution is added to make the pH neutral.
(8) In some cases, 10 to 50000 unit amylase may be added per liter of the medium, and the wheat starch may be partially digested by incubating at 10 to 80 ° C. for 1 to 24 hours.
(9) Add pantoea agglomerans isolated in 1 to 7-8.
(10) Ferment 9 at 1-40 ° C. In some cases, it may be left still or shaken. Further, stirring may be performed every several hours.
(11) Ferment 10 for 6 hours to 1 week. As the fermentation progresses, the aqueous wheat flour solution becomes yellow.
(12) It is also possible to add an alkaline solution as appropriate during the fermentation of 11 to make the pH neutral, or to add a flour suspension or inorganic salts.
(13) The fermentation is terminated, and the solid content is recovered as a precipitate by an operation such as centrifugation (1000 to 5000 rpm, 10 to 60 minutes).
(14) 13 is suspended in water or a salt buffer, and this is heated at 80 to 140 ° C. for 10 minutes to 6 hours. Further, the solid content may be removed by centrifugation, activated carbon treatment, filtration, or the like. Water or a buffer solution may be added again to the removed precipitate, and the heat extraction may be repeated several times. If this is dried, it can also be made into a powder.
(15) The wheat fermented extract produced in 14 can be further refined depending on the application. That is, when a salt such as sodium chloride is added to 14 extracts to a final concentration of 0.05 to 1 mol / l, and then a solvent such as ethanol is added 1 to 3 times the amount of the extract, precipitation occurs. . You may collect this with a centrifuge. This precipitate may be further washed with a solvent such as ethanol. If this is dried, it can also be made into powder.

Sample preparation Samples include hojicha extract, indigestible dextrin, Salacia oblonga extract, fermented wheat extract (powder of production method (14)) (20 mg), vitamin premix (dibenzoylthiamine hydrochloride 0.32 mg, riboflavin phosphorus Sodium acid ester 0.27 mg, nicotinamide 1.63 mg, calcium pantothenate 0.96 mg, pyridoxine hydrochloride 0.28 mg, cyanocobalamin 0.75 μg, L-ascorbic acid (VC) 7.5 mg), oligosaccharide and cyclic oligosaccharide were mixed. This was packaged at 1.0 grams per packet.

Result 1. Reduction effect of HbA1c Changes in HbA1c in each group were measured. The value before 60 days for each person was taken as 1, and the value for 60 days was shown as a ratio. HbA1c (hemoglobin A1C) is a combination of hemoglobin and sugar, and is used as an index that can measure the average value of blood glucose levels in the past about 1 to 3 months by examining HtA1C.

**：p＜0.01 （事前測定値との比較）

**: p <0.01 (comparison with prior measurement)

  There was no significant change in the S group, the P group, and the Y group in the diabetic preparatory group A after 60 days of ingestion. Only the S group of the B group in the dyslipidemia preparatory group decreased significantly after 60 days. From this, a decrease in blood glucose level in the preparatory group for dyslipidemia was observed only in the wheat fermented extract and Salacia oblonga combination group.

Result 2. LDL reduction effect Changes in LDL in each group were measured. The measurement value before each person's measurement was taken as 1, and the values for 30 days and 60 days were shown as a ratio.

*：p＜0.05 （事前測定値との比較）

*: P <0.05 (comparison with prior measurements)

  After 30 days of intake, no significant changes were observed in the S group, P group, and Y group in the diabetic reserve group A and the dyslipidemia reserve group B. After 60 days of intake, group A showed a significant LDL reduction effect in group S, but no significant change was observed in groups P and Y. In group B, there was no significant change in groups S, P and Y. Therefore, it was observed that only the fermented wheat extract and Salacia oblonga combination group decreased the LDL value of the diabetic reserve group.

Result 3. Increased effect of HDL Changes in HDL in each group were measured. The measurement value before each person's measurement was taken as 1, and the value for 30 days or 60 days was shown as a ratio.

*：p＜0.05 （事前測定値との比較）

*: P <0.05 (comparison with prior measurements)

  After 30 days of intake, group A showed a significant LDL reduction effect in group S, but no significant change was observed in groups P and Y. There was no significant change in the S group, the P group, and the Y group in the A group of the diabetes preparatory group and the B group of the dyslipidemia preliminary group after 60 days of intake. From this, it was observed that only the wheat fermented extract and Salacia oblonga combined group increased the HDL value of the diabetic preparatory group.

In addition, although Salacia oblonga was used in the examples, the present invention is not limited to this, and the components salacinol, cotaranol, and mangiferin exhibit a glucosidase inhibitory action, so that any plant containing a glucose oxidase inhibitor has the same effect. It is clear. Specifically, in addition to plants of the genus Salacia, extracts of maou (see patent document 3), allspice, clove (see patent document 4), rafma, keihi, eucalyptus, and loquat (see patent document 5), etc. However, it is clear that the same effect is achieved.

Claims (4)

  An extract obtained by fermenting wheat flour with facultative anaerobic gram-negative bacteria symbiotic to a plant and simultaneously culturing the facultative anaerobic gram-negative bacteria (hereinafter referred to as “wheat fermentation extract”) and A wheat fermented extract blend comprising an extract of a plant of the genus Salacia.   A wheat fermented extract composition comprising a fermented wheat extract and Salacia oblonga.   A wheat fermented extract composition comprising a fermented wheat extract and an extract of mao, allspice, clove, rafma, keihi, eucalyptus, or loquat. 4. The wheat according to any one of claims 1 to 3, wherein the wheat fermented extract blend is a pharmaceutical product, a pharmaceutical product for pets, a quasi-drug, a food, a functional food, a pet feed or a bath preparation. Fermented extract formulation.